Goldman Sachs Maintains Neutral on TG Therapeutics, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Corinne Jenkins maintains a Neutral rating on TG Therapeutics (NASDAQ:TGTX) and raises the price target from $18 to $20.
August 07, 2024 | 4:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs maintains a Neutral rating on TG Therapeutics and raises the price target from $18 to $20.
The raised price target from $18 to $20 by a reputable firm like Goldman Sachs is a positive signal for investors, indicating potential upside. However, the Neutral rating suggests a balanced view on the stock's immediate prospects.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100